Format

Send to

Choose Destination
Biol Psychiatry. 2016 Sep 15;80(6):439-447. doi: 10.1016/j.biopsych.2015.11.027. Epub 2015 Dec 15.

Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder.

Author information

1
Ewha Brain Institute and Department of Brain and Cognitive Sciences, Ewha W. University, Seoul, South Korea.
2
Department of Psychiatry, Soonchunhyang University College of Medicine, Seoul, South Korea.
3
Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea.
4
Brain Institute and Department of Psychiatry, University of Utah, Salt Lake City, Utah.
5
Ewha Brain Institute and Department of Brain and Cognitive Sciences, Ewha W. University, Seoul, South Korea; Brain Institute and Department of Psychiatry, University of Utah, Salt Lake City, Utah. Electronic address: inkylyoo@ewha.ac.kr.

Abstract

BACKGROUND:

Creatine monohydrate (creatine) augmentation has the potential to accelerate the clinical responses to and enhance the overall efficacy of selective serotonin reuptake inhibitor treatment in women with major depressive disorder (MDD). Although it has been suggested that creatine augmentation may involve the restoration of brain energy metabolism, the mechanisms underlying its antidepressant efficacy are unknown.

METHODS:

In a randomized, double-blind, placebo-controlled trial, 52 women with MDD were assigned to receive either creatine augmentation or placebo augmentation of escitalopram; 34 subjects participated in multimodal neuroimaging assessments at baseline and week 8. Age-matched healthy women (n = 39) were also assessed twice at the same intervals. Metabolic and network outcomes were measured for changes in prefrontal N-acetylaspartate and changes in rich club hub connections of the structural brain network using proton magnetic resonance spectroscopy and diffusion tensor imaging, respectively.

RESULTS:

We found MDD-related metabolic and network dysfunction at baseline. Improvement in depressive symptoms was greater in patients receiving creatine augmentation relative to placebo augmentation. After 8 weeks of treatment, prefrontal N-acetylaspartate levels increased significantly in the creatine augmentation group compared with the placebo augmentation group. Increment in rich club hub connections was also greater in the creatine augmentation group than in the placebo augmentation group.

CONCLUSIONS:

N-acetylaspartate levels and rich club connections increased after creatine augmentation of selective serotonin reuptake inhibitor treatment. Effects of creatine administration on brain energy metabolism and network organization may partly underlie its efficacy in treating women with MDD.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00729755.

KEYWORDS:

Antidepressant; Brain bioenergetics; Creatine monohydrate; Major depressive disorder; Network organization; Selective serotonin reuptake inhibitor

PMID:
26822799
DOI:
10.1016/j.biopsych.2015.11.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center